PDF(Pubmed)
Abstract：
UNASSIGNED: Chemerin, as a novel multifunctional adipokine, is proposed to be involved in high cancer risk and mortality. The present study was aimed to evaluate the prognostic value of serum Chemerin and neutrophils in patients with oral squamous cell carcinoma (OSCC).
UNASSIGNED: 120 patients with OSCC were included in this prospective cohort study. The levels of serum Chemerin were measured by enzyme-linked immunosorbent assay (ELISA). We also explored the possible effects of Chemerin on neutrophils\' chemokines in OSCC using a real-time PCR, western blotting.
UNASSIGNED: Levels of serum Chemerin, neutrophils and NLR were significantly higher among non-survivors compared to survivors of OSCC (both P < 0.05). Higher serum Chemerin levels were associated with advanced TNM stage, lymph node metastasis, differentiation and tumor recurrence (both P < 0.05). Serum Chemerin levels correlated with neutrophils and NLR levels (r = 0.708, r = 0.578, both P < 0.05). Based on ROC analysis, Chemerin + NLR predicted OSCC patient mortality with 81.54 % sensitivity and 87.27 % specificity, with an AUC of 0.8898. In a Kaplan-Meier analysis, high serum Chemerin levels, high neutrophil levels and high NLR levels were associated with shorter overall and disease-free survival (both P < 0.05). A univariate and multivariate Cox regression analysis showed that serum Chemerin and neutrophils were independent risk factors for OSCC. (both P < 0.05). QRT-PCR and western blotting results showed that Chemerin upregulated the expression of chemokines IL-17 and CXCL-5 in neutrophils (both P < 0.05).
UNASSIGNED: Our study suggests that measurement of serum Chemerin and neutrophils might be a useful diagnostic and prognostic biomarker for OSCC patients. Chemerin may promote neutrophils infiltration in OSCC through upregulation of chemokines IL17 and CXCL-5.
UNASSIGNED: 120 patients with OSCC were included in this prospective cohort study. The levels of serum Chemerin were measured by enzyme-linked immunosorbent assay (ELISA). We also explored the possible effects of Chemerin on neutrophils\' chemokines in OSCC using a real-time PCR, western blotting.
UNASSIGNED: Levels of serum Chemerin, neutrophils and NLR were significantly higher among non-survivors compared to survivors of OSCC (both P < 0.05). Higher serum Chemerin levels were associated with advanced TNM stage, lymph node metastasis, differentiation and tumor recurrence (both P < 0.05). Serum Chemerin levels correlated with neutrophils and NLR levels (r = 0.708, r = 0.578, both P < 0.05). Based on ROC analysis, Chemerin + NLR predicted OSCC patient mortality with 81.54 % sensitivity and 87.27 % specificity, with an AUC of 0.8898. In a Kaplan-Meier analysis, high serum Chemerin levels, high neutrophil levels and high NLR levels were associated with shorter overall and disease-free survival (both P < 0.05). A univariate and multivariate Cox regression analysis showed that serum Chemerin and neutrophils were independent risk factors for OSCC. (both P < 0.05). QRT-PCR and western blotting results showed that Chemerin upregulated the expression of chemokines IL-17 and CXCL-5 in neutrophils (both P < 0.05).
UNASSIGNED: Our study suggests that measurement of serum Chemerin and neutrophils might be a useful diagnostic and prognostic biomarker for OSCC patients. Chemerin may promote neutrophils infiltration in OSCC through upregulation of chemokines IL17 and CXCL-5.
摘要：
■Chemerin,作为一种新颖的多功能脂肪因子，被提议参与高癌症风险和死亡率。本研究旨在评估血清Chemerin和中性粒细胞对口腔鳞状细胞癌（OSCC）患者的预后价值。
■120例OSCC患者纳入本前瞻性队列研究。采用酶联免疫吸附试验(ELISA)检测血清Chemerin水平。我们还使用实时PCR探索了Chemerin对OSCC中性粒细胞趋化因子的可能影响，西方印迹。
■血清Chemerin水平，与OSCC的幸存者相比,非幸存者的中性粒细胞和NLR显著升高(均P<0.05)。较高的血清Chemerin水平与晚期TNM分期相关，淋巴结转移,分化与肿瘤复发(均P<0.05)。血清Chemerin水平与中性粒细胞和NLR水平相关(r=0.708,r=0.578,均P<0.05)。基于ROC分析,Chemerin+NLR预测OSCC患者死亡率的敏感性为81.54%，特异性为87.27%。AUC为0.8898。在Kaplan-Meier分析中,高血清Chemerin水平，高中性粒细胞水平和高NLR水平与较短的总生存期和无病生存期相关(均P<0.05).单因素和多因素Cox回归分析显示血清Chemerin和中性粒细胞是OSCC的独立危险因素。(均P<0.05)。QRT-PCR和Westernblotting结果显示,Chemerin上调中性粒细胞中趋化因子IL-17和CXCL-5的表达(均P<0.05)。
■我们的研究表明，血清Chemerin和中性粒细胞的测量可能是OSCC患者的有用的诊断和预后生物标志物。Chemerin可通过上调趋化因子IL17和CXCL-5促进OSCC中的嗜中性粒细胞浸润。
■120例OSCC患者纳入本前瞻性队列研究。采用酶联免疫吸附试验(ELISA)检测血清Chemerin水平。我们还使用实时PCR探索了Chemerin对OSCC中性粒细胞趋化因子的可能影响，西方印迹。
■血清Chemerin水平，与OSCC的幸存者相比,非幸存者的中性粒细胞和NLR显著升高(均P<0.05)。较高的血清Chemerin水平与晚期TNM分期相关，淋巴结转移,分化与肿瘤复发(均P<0.05)。血清Chemerin水平与中性粒细胞和NLR水平相关(r=0.708,r=0.578,均P<0.05)。基于ROC分析,Chemerin+NLR预测OSCC患者死亡率的敏感性为81.54%，特异性为87.27%。AUC为0.8898。在Kaplan-Meier分析中,高血清Chemerin水平，高中性粒细胞水平和高NLR水平与较短的总生存期和无病生存期相关(均P<0.05).单因素和多因素Cox回归分析显示血清Chemerin和中性粒细胞是OSCC的独立危险因素。(均P<0.05)。QRT-PCR和Westernblotting结果显示,Chemerin上调中性粒细胞中趋化因子IL-17和CXCL-5的表达(均P<0.05)。
■我们的研究表明，血清Chemerin和中性粒细胞的测量可能是OSCC患者的有用的诊断和预后生物标志物。Chemerin可通过上调趋化因子IL17和CXCL-5促进OSCC中的嗜中性粒细胞浸润。
